S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:AXSM

Axsome Therapeutics - AXSM Stock Forecast, Price & News

$46.27
+0.95 (+2.10%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$45.12
$47.12
50-Day Range
$21.74
$48.36
52-Week Range
$19.38
$48.82
Volume
597,361 shs
Average Volume
1.11 million shs
Market Capitalization
$1.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$95.00

Axsome Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
95.9% Upside
$90.63 Price Target
Short Interest
Bearish
18.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.60mentions of Axsome Therapeutics in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.99) to ($1.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

315th out of 1,117 stocks

Pharmaceutical Preparations Industry

154th out of 550 stocks

AXSM stock logo

About Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics Trading Up 2.1 %

NASDAQ:AXSM traded up $0.95 on Friday, hitting $46.27. 597,361 shares of the stock were exchanged, compared to its average volume of 1,113,164. The company has a debt-to-equity ratio of 6.15, a quick ratio of 3.54 and a current ratio of 2.44. The stock has a fifty day moving average price of $36.27 and a two-hundred day moving average price of $33.63. The firm has a market capitalization of $1.80 billion, a P/E ratio of -11.80 and a beta of 1.92. Axsome Therapeutics has a 52-week low of $19.38 and a 52-week high of $48.82.

Axsome Therapeutics (NASDAQ:AXSM - Get Rating) last issued its earnings results on Tuesday, August 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.19) by $0.13. During the same quarter in the previous year, the business earned ($0.86) EPS. Research analysts forecast that Axsome Therapeutics will post -3.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on AXSM shares. Mizuho dropped their price objective on shares of Axsome Therapeutics from $51.00 to $49.00 in a report on Tuesday, May 3rd. Cowen raised their target price on shares of Axsome Therapeutics from $120.00 to $130.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 29th. Cantor Fitzgerald reduced their price objective on shares of Axsome Therapeutics from $64.00 to $54.00 in a research report on Wednesday. Cowen lifted their price objective on shares of Axsome Therapeutics from $120.00 to $130.00 and gave the company an "outperform" rating in a research report on Wednesday, June 29th. Finally, Morgan Stanley lifted their price objective on shares of Axsome Therapeutics from $54.00 to $55.00 and gave the company an "equal weight" rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $90.63.

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock News Headlines

Axsome Therapeutics Whale Trades For August 12
Axsome Therapeutics (NASDAQ:AXSM) Trading Down 3.4%
Axsome: One Step At A Time
2 Biotechs That Recently Soared -- Are They Buys?
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Company Calendar

Last Earnings
8/09/2022
Today
8/12/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXSM
Employees
108
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$90.63
High Stock Price Forecast
$180.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+105.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
9 Analysts

Profitability

Net Income
$-130,400,000.00
Pretax Margin
-1,699.89%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.39 per share

Miscellaneous

Free Float
28,796,000
Market Cap
$1.80 billion
Optionable
Optionable
Beta
1.92

Key Executives

  • Dr. Herriot Tabuteau M.D. (Age 54)
    Founder, Chairman, CEO & Pres
    Comp: $1.06M
  • Mr. Nick Pizzie CPA (Age 47)
    M.B.A., Chief Financial Officer
    Comp: $553.97k
  • Mr. Mark L. Jacobson (Age 39)
    COO & Sec.
    Comp: $554.72k
  • Mr. Hunter Murdock Esq.
    Exec. VP of Legal & Compliance
  • Dr. Amanda Jones Pharm.D. (Age 39)
    Sr. VP of Clinical Devel.
  • Ms. Lori Englebert M.B.A. (Age 44)
    Exec. VP of Commercial & Bus. Devel.
  • Mr. Kevin Laliberte Pharm.D. (Age 44)
    Exec. VP of Product Strategy
  • Joseph Debrah-Afful CPA
    M.B.A., Director of Fin.













AXSM Stock - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price forecast for 2022?

9 analysts have issued twelve-month price targets for Axsome Therapeutics' stock. Their AXSM share price forecasts range from $49.00 to $180.00. On average, they predict the company's stock price to reach $90.63 in the next twelve months. This suggests a possible upside of 95.2% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2022?

Axsome Therapeutics' stock was trading at $37.78 at the start of the year. Since then, AXSM stock has increased by 22.9% and is now trading at $46.43.
View the best growth stocks for 2022 here
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AXSM earnings forecast
.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its earnings results on Tuesday, August, 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.19) by $0.13. During the same period in the previous year, the firm posted ($0.86) earnings per share.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Iridian Asset Management LLC CT (1.40%), Group One Trading L.P. (0.00%), Pictet Asset Management SA (0.91%), US Bancorp DE (0.68%), FMR LLC (0.61%) and JPMorgan Chase & Co. (0.45%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends
.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $46.43.

How much money does Axsome Therapeutics make?

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $1.81 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

How many employees does Axsome Therapeutics have?

The company employs 108 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.

This page (NASDAQ:AXSM) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.